Atopic Dermatitis Affects Millions, And Johnson & Johnson Is Committed To Addressing The Unmet Needs Of Patients
AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...
Cosmetics Business7d
Innovating for atopic dermatitis: Cutting-edge solutions by Eurofins
Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...
Revolo to Present at the 2025 AAAAI / WAO Joint Congress
More information about the 2025 AAAAI / WAO Joint Congress can be accessed here.
New targeted therapy could bring relief to people with lichen planus
Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...
GEN8d
Cancer Immunotherapy: From Nineteenth-Century Beginnings to Modern Breakthroughs
Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...
technologynetworks9d
Targeted Therapy Shows Effectiveness in Skin Disease Patients
Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...
Medscape4d
Could Gene Therapy for RA Soon Be Ready to ‘Take Off’?
Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...
Le Lézard8d
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines. Dysregulation ...